171 related articles for article (PubMed ID: 17092842)
21. Targeting tumor angiogenic vasculature using polymer-RGD conjugates.
Mitra A; Mulholland J; Nan A; McNeill E; Ghandehari H; Line BR
J Control Release; 2005 Jan; 102(1):191-201. PubMed ID: 15653145
[TBL] [Abstract][Full Text] [Related]
22. Endocytotic uptake of HPMA-based polymers by different cancer cells: impact of extracellular acidosis and hypoxia.
Gündel D; Allmeroth M; Reime S; Zentel R; Thews O
Int J Nanomedicine; 2017; 12():5571-5584. PubMed ID: 28831253
[TBL] [Abstract][Full Text] [Related]
23. Transiently Responsive Block Copolymer Micelles Based on N-(2-Hydroxypropyl)methacrylamide Engineered with Hydrolyzable Ethylcarbonate Side Chains.
Kasmi S; Louage B; Nuhn L; Van Driessche A; Van Deun J; Karalic I; Risseeuw M; Van Calenbergh S; Hoogenboom R; De Rycke R; De Wever O; Hennink WE; De Geest BG
Biomacromolecules; 2016 Jan; 17(1):119-27. PubMed ID: 26650350
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of cytotoxicity in human ovarian carcinoma cells exposed to free Mce6 or HPMA copolymer-Mce6 conjugates.
Tijerina M; Kopecková P; Kopecek J
Photochem Photobiol; 2003 Jun; 77(6):645-52. PubMed ID: 12870851
[TBL] [Abstract][Full Text] [Related]
25. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
[TBL] [Abstract][Full Text] [Related]
26. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.
Duncan R; Vicent MJ
Adv Drug Deliv Rev; 2010 Feb; 62(2):272-82. PubMed ID: 20005271
[TBL] [Abstract][Full Text] [Related]
27. Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats.
Pan H; Sima M; Miller SC; Kopečková P; Yang J; Kopeček J
Biomaterials; 2013 Sep; 34(27):6528-38. PubMed ID: 23731780
[TBL] [Abstract][Full Text] [Related]
28. HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.
Greco F; Vicent MJ; Penning NA; Nicholson RI; Duncan R
J Drug Target; 2005; 13(8-9):459-70. PubMed ID: 16332571
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
30. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
31. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
[TBL] [Abstract][Full Text] [Related]
32. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
Line BR; Mitra A; Nan A; Ghandehari H
J Nucl Med; 2005 Sep; 46(9):1552-60. PubMed ID: 16157540
[TBL] [Abstract][Full Text] [Related]
33. [Selective tumor-accumulation of HPMA copolymer-mitoxantrone conjugates].
Huang Y; Zhang ZR
Yao Xue Xue Bao; 2004 May; 39(5):374-9. PubMed ID: 15338883
[TBL] [Abstract][Full Text] [Related]
34. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
35. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.
Borgman MP; Aras O; Geyser-Stoops S; Sausville EA; Ghandehari H
Mol Pharm; 2009; 6(6):1836-47. PubMed ID: 19743884
[TBL] [Abstract][Full Text] [Related]
36. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
[TBL] [Abstract][Full Text] [Related]
37. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.
Omelyanenko V; Gentry C; Kopecková P; Kopecek J
Int J Cancer; 1998 Feb; 75(4):600-8. PubMed ID: 9466663
[TBL] [Abstract][Full Text] [Related]
38. Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates.
Paul A; Vicent MJ; Duncan R
Biomacromolecules; 2007 May; 8(5):1573-9. PubMed ID: 17419585
[TBL] [Abstract][Full Text] [Related]
39. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.
Yeung TK; Hopewell JW; Simmonds RH; Seymour LW; Duncan R; Bellini O; Grandi M; Spreafico F; Strohalm J; Ulbrich K
Cancer Chemother Pharmacol; 1991; 29(2):105-11. PubMed ID: 1760851
[TBL] [Abstract][Full Text] [Related]
40. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
